Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 1265162 add-on therapy in cystic fibrosis
2019-000261-21Phase 2Terminated
- Sponsor
- Boehringer Ingelheim
- Start
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of BI 1265162 in cystic fibrosis (CF) (5 arms), sponsored by Boehringer Ingelheim. Primary endpoint: Change from baseline in percent predicted trough Forced Expiratory Volume in 1 second after 4 weeks. Started Apr 2019; status: terminated.
02
Drugs
BI 1265162
03
Conditions
cystic fibrosis (CF)
Beyond the preview
Go deeper on 2019-000261-21.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-000261-21.